利培酮口服液与奥氮平治疗脑器质性精神障碍疗效与安全性分析

目的 比较利培酮口服液与奥氮平在治疗脑器质性精神障碍疗效与安全性的差异。方法 分析2007年5月至2011年5月在本院住院4周以上,符合CCMD-3中脑器质性精神障碍诊断标准的患者共133例,其中利培酮口服液组62例,奥氮平组71例。比较两组患者入院时与治疗4周末在简明精神病评定量表、阳性症状量表、阴性症状量表、副反应量表总分以及实验室检查上的差异。结果 两组在治疗4周末简明精神病评定量表、阳性症状量表、阴性症状量表分值上无统计学差异(P>0.05)。在锥体外系副反应,催乳素水平升高上利培酮口服液组要大于奥氮平组(P<0.05),而在体重增加和镇静、嗜睡上要少于奥氮平组(P<0.05);在其余副反应项目的 比较上则未见统计学差异(P>0.05)。结论 利培酮口服液与奥氮平对脑器质性精神障碍的治疗效果是相当的,对脑炎所致精神障碍的有效率在80%左右,两者在副反应上有所差别,在临床治疗时需根据患者具体情况制定个体化治疗方案。

A retrospective study of risperidone oral solution versus olanzapine tablets in treating brain organic mental disorders

AIM: To retrospectively evaluate the efficacy and safety of risperidone oral solution and olanzapine tablets in treating brain organic mental disorders. METHODS: A total of 133 patients, who met diagnostic criteria of CCMD-3 for brain organic mental disorders and were hospitalized in department of psychiatry from May 2007 to May 2011, included 62 patients in risperidone oral solution group and 71 patients in olanzapine tablets group. On the pre-treatment and at the end of the 4th week of treatment, all patients were assessed by Brief Psychiatric Rating Scale(BPRS), Scale for the Assessment of Negative Symptoms (SANS), Scale for the Assessment of Positive Symptoms(SAPS),Treatment Emergent Symptom Scale (TESS) and laboratory tests.RESULTS: There were significant difference in extrapyramidal side effects, prolactin levels, sleepiness and weight gain between pre-treatment and post-treatment(32.3% vs 16.9%,19.4% vs 5.6%,6.5% vs 19.7%,9.7% vs 19.6%, P<0.05) . However, there were no statistically significant difference(P>0.05) in the total scales of BPRS, SANS, SAPS ,TESS and other index of safety.CONCLUSION: The efficacy of risperidone oral solution and olanzapine tablets in treating brain organic mental disorders was equal, especially for mental disorder due to encephalitis the efficacy up to about 80%, but there were some differences in side effects. It was needed to arrange the treating program according to the patients conditions.